JP2021119136A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021119136A5 JP2021119136A5 JP2021060013A JP2021060013A JP2021119136A5 JP 2021119136 A5 JP2021119136 A5 JP 2021119136A5 JP 2021060013 A JP2021060013 A JP 2021060013A JP 2021060013 A JP2021060013 A JP 2021060013A JP 2021119136 A5 JP2021119136 A5 JP 2021119136A5
- Authority
- JP
- Japan
- Prior art keywords
- temperature
- disease
- compound
- xrpd
- crystal according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims 2
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000001237 Raman spectrum Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166641.9A EP3090998A1 (en) | 2015-05-06 | 2015-05-06 | Solid forms |
| EP15166641.9 | 2015-05-06 | ||
| JP2017557899A JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557899A Division JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021119136A JP2021119136A (ja) | 2021-08-12 |
| JP2021119136A5 true JP2021119136A5 (https=) | 2021-11-25 |
Family
ID=53039825
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557899A Active JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
| JP2021060013A Pending JP2021119136A (ja) | 2015-05-06 | 2021-03-31 | 固体形態 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557899A Active JP7005007B2 (ja) | 2015-05-06 | 2016-05-02 | 固体形態 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10221125B2 (https=) |
| EP (2) | EP3090998A1 (https=) |
| JP (2) | JP7005007B2 (https=) |
| KR (1) | KR102666390B1 (https=) |
| CN (1) | CN107735394B (https=) |
| AR (1) | AR104505A1 (https=) |
| AU (1) | AU2016259054B2 (https=) |
| BR (1) | BR112017023740B1 (https=) |
| CA (1) | CA2984203C (https=) |
| ES (1) | ES2969970T3 (https=) |
| HU (1) | HUE065558T2 (https=) |
| IL (1) | IL255194B (https=) |
| MX (1) | MX378732B (https=) |
| PL (1) | PL3292100T3 (https=) |
| WO (1) | WO2016177656A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| CA3017408C (en) | 2016-03-15 | 2025-08-19 | Oryzon Genomics, S.A. | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| RS58951B1 (sr) | 2016-06-10 | 2019-08-30 | Oryzon Genomics Sa | Lečenje multiple skleroze |
| FI3661510T3 (fi) | 2017-08-03 | 2024-12-18 | Oryzon Genomics Sa | Menetelmiä käyttäytymismuutosten hoitamiseksi |
| JP2021522305A (ja) * | 2018-05-04 | 2021-08-30 | オリソン ヘノミクス，ソシエダ アノニマ | 安定した医薬製剤 |
| LT3941466T (lt) | 2019-03-20 | 2026-02-25 | Oryzon Genomics, S.A. | Vafidemstatas ribinio asmenybės sutrikimo simptomų, nesusijusių su agresija, gydymui |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| MX2021011610A (es) * | 2019-03-25 | 2021-10-13 | Oryzon Genomics Sa | Combinaciones de iadademstat para terapia contra el cancer. |
| CN114341366A (zh) | 2019-07-05 | 2022-04-12 | 奥莱松基因组股份有限公司 | 用于使用kdm1a抑制剂个体化治疗小细胞肺癌的生物标志物和方法 |
| US20250073232A1 (en) | 2021-04-08 | 2025-03-06 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006071608A2 (en) | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
| ES2349544T3 (es) | 2005-02-18 | 2011-01-04 | Universitätsklinikum Freiburg | Control de la expresión génica dependiente de receptores de andrógenos inhibiendo la actividad de amina oxidasa de la demetilasa lisina-específica (lsd1). |
| WO2007021839A2 (en) | 2005-08-10 | 2007-02-22 | Johns Hopkins University | Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors |
| EP2142287A4 (en) | 2007-04-13 | 2012-05-23 | Univ Johns Hopkins | INHIBITORS OF LYSINPECIFIC DEMETHYLASE |
| WO2010011845A2 (en) | 2008-07-24 | 2010-01-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods of preventing or treating viral infection or reactivation after latency in a host using inhibitors of the lsd1 protein |
| WO2010043721A1 (en) | 2008-10-17 | 2010-04-22 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
| US8993808B2 (en) | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
| EP2258865A1 (en) | 2009-06-05 | 2010-12-08 | Universitätsklinikum Freiburg | Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer |
| JPWO2010143582A1 (ja) | 2009-06-11 | 2012-11-22 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びｌｓｄ１阻害剤 |
| EP2467359A4 (en) | 2009-08-18 | 2013-01-09 | Univ Johns Hopkins | (BIS-) UREA- AND (BIS-) THIOMINE COMPOUNDS AS EPIGENE MODULATORS OF THE LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF DISEASE TREATMENT THEREWITH |
| US8859555B2 (en) | 2009-09-25 | 2014-10-14 | Oryzon Genomics S.A. | Lysine Specific Demethylase-1 inhibitors and their use |
| EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
| WO2011106106A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae |
| WO2011106574A2 (en) | 2010-02-24 | 2011-09-01 | Oryzon Genomics, S.A. | Inhibitors for antiviral use |
| US20130197088A1 (en) | 2010-03-12 | 2013-08-01 | Robert A. Casero, JR. | Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO) |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| BR112012027062B8 (pt) | 2010-04-20 | 2021-05-25 | Fond Ieo | composto, processo para a preparação de um composto e usos do mesmo |
| US9006449B2 (en) | 2010-07-29 | 2015-04-14 | Oryzon Genomics, S.A. | Cyclopropylamine derivatives useful as LSD1 inhibitors |
| BR112013002164B1 (pt) | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| WO2012034116A2 (en) | 2010-09-10 | 2012-03-15 | The Johns Hopkins University | Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders |
| US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
| US9061966B2 (en) | 2010-10-08 | 2015-06-23 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
| WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
| EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
| EP2712316A1 (en) | 2011-02-08 | 2014-04-02 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| US20140296255A1 (en) | 2011-05-19 | 2014-10-02 | Oryzong Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
| US20140329833A1 (en) | 2011-05-19 | 2014-11-06 | Oryzon Genomics, S.A | Lysine demethylase inhibitors for inflammatory diseases or conditions |
| EP2768805B1 (en) | 2011-10-20 | 2020-03-25 | Oryzon Genomics, S.A. | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
| JP6046154B2 (ja) * | 2011-10-20 | 2016-12-14 | オリソン ヘノミクス エセ． アー． | Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物 |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| AU2016275702A1 (en) | 2015-06-12 | 2017-12-21 | Oryzon Genomics, S.A. | Biomarkers associated with LSD1 inhibitors and uses thereof |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| EP3359684A1 (en) | 2015-10-09 | 2018-08-15 | Oryzon Genomics, S.A. | Gene expression biomarkers for personalized cancer care to epigenetic modifying agents |
| CA3017408C (en) | 2016-03-15 | 2025-08-19 | Oryzon Genomics, S.A. | LSD1 INHIBITOR COMBINATIONS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIS |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| EP3535414A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
-
2015
- 2015-05-06 EP EP15166641.9A patent/EP3090998A1/en not_active Ceased
-
2016
- 2016-05-02 US US15/571,945 patent/US10221125B2/en active Active
- 2016-05-02 WO PCT/EP2016/059726 patent/WO2016177656A1/en not_active Ceased
- 2016-05-02 PL PL16719864.7T patent/PL3292100T3/pl unknown
- 2016-05-02 AU AU2016259054A patent/AU2016259054B2/en active Active
- 2016-05-02 MX MX2017014035A patent/MX378732B/es unknown
- 2016-05-02 CA CA2984203A patent/CA2984203C/en active Active
- 2016-05-02 JP JP2017557899A patent/JP7005007B2/ja active Active
- 2016-05-02 EP EP16719864.7A patent/EP3292100B1/en active Active
- 2016-05-02 CN CN201680025229.8A patent/CN107735394B/zh active Active
- 2016-05-02 BR BR112017023740-7A patent/BR112017023740B1/pt active IP Right Grant
- 2016-05-02 KR KR1020177035160A patent/KR102666390B1/ko active Active
- 2016-05-02 ES ES16719864T patent/ES2969970T3/es active Active
- 2016-05-02 HU HUE16719864A patent/HUE065558T2/hu unknown
- 2016-05-03 AR ARP160101249A patent/AR104505A1/es unknown
-
2017
- 2017-10-22 IL IL255194A patent/IL255194B/en active IP Right Grant
-
2021
- 2021-03-31 JP JP2021060013A patent/JP2021119136A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021119136A5 (https=) | ||
| JP2018516883A5 (https=) | ||
| JPWO2022138988A5 (https=) | ||
| JP2023519891A5 (https=) | ||
| CN101528762A (zh) | 5-氨基-3-(2′,3′-二-O-乙酰基-β-D-呋喃核糖基)-3H-噻唑并[4,5-D]嘧啶-2-酮的马来酸盐的结晶A和B形式 | |
| JP2023530785A5 (https=) | ||
| US10710961B2 (en) | Method for preparing intermediate of 4-methoxypyrrole derivative | |
| US11028069B2 (en) | Salt of substituted piperidine compound | |
| JP2019503993A (ja) | テトラサイクリンの塩 | |
| TW201514165A (zh) | Ｄ-葡萄糖醇，１-脫氧-１-（甲胺基）-，-１-（６-胺基-３，５-二氟吡啶-２-基）-８-氯-６-氟-１，４-二氫-７-（３-羥基氮雜環丁烷-１-基）-４-側氧基-３-喹啉羧酸的結晶形態與其製備程序 | |
| EA013005B1 (ru) | Производное изоксазолина и новый способ его получения | |
| JP2023530786A5 (https=) | ||
| CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
| JP2005529084A5 (https=) | ||
| RU2451016C2 (ru) | Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида | |
| RU2007143025A (ru) | Полиморфизм додекагидроклопента[а]фенантренилового эфира тиофенкарбоновой кислоты | |
| CN108299279A (zh) | 取代芳基胺醇化合物及其制备方法和用途 | |
| JP7132211B2 (ja) | ３－（３，５－ジクロロ－４－ヒドロキシベンゾイル）－１，１－ジオキソ－２，３－ジヒドロ－１，３－ベンゾチアゾールの結晶形及び塩 | |
| CN1452613A (zh) | 无定形的托拉塞米变体 | |
| JPWO2002083633A1 (ja) | トシル酸スプラタスト結晶 | |
| CN1880294B (zh) | 右酮洛芬氨丁三醇的多晶型、其制备方法和包含它的组合物 | |
| US20220402861A1 (en) | A Crystalline form of (R)-terbutaline Hydrochloride | |
| CN104768927B (zh) | (3s,3s’)‑4,4’‑二硫烷二基双(3‑氨基丁烷‑1‑磺酸)合l‑赖氨酸的新的结晶相 | |
| US7943655B2 (en) | Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use | |
| CN106478603B (zh) | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 |